Balaxi Pharmaceuticals Limited Q2 Revenue Rises 44.8% in FY27

Balaxi Pharmaceuticals Limited reported consolidated revenue of ₹81.37 crore for Q2 FY27, up 44.8% year-on-year, while net profit rose 450.3% to ₹1.15 crore for the quarter ended 30 September 2026. The result reflects higher sales and a sharp improvement in operating profit, although profit declined sequentially from Q1 FY27.

What did Balaxi Pharmaceuticals report for Q2 FY27?

Balaxi Pharmaceuticals reported revenue from operations of ₹81.37 crore in the July-September 2026 quarter, compared with ₹56.18 crore in Q2 FY26. Total income increased 39.4% year-on-year to ₹80.54 crore from ₹57.76 crore, based on the consolidated unaudited financial results approved by the board.

Operating profit, calculated from the filing as EBITDA, rose to ₹5.12 crore from ₹1.17 crore a year earlier. This represented growth of 338.2%, while the operating margin expanded to 6.29% from 2.08%. Profit before tax increased to ₹2.02 crore from ₹1.38 crore.

Net profit was ₹1.15 crore, compared with ₹0.21 crore in the year-ago period. The increase followed the improvement in operating profit and lower tax expense compared with Q2 FY26. Diluted earnings per share rose to ₹0.21 from ₹0.04.

How did the quarter compare with Q1 FY27?

Balaxi Pharmaceuticals recorded modest sequential revenue growth, but net profit was lower than in the preceding quarter. Revenue from operations increased 0.9% from ₹80.68 crore in Q1 FY27 to ₹81.37 crore in Q2 FY27, while total income rose 1.1% from ₹79.69 crore.

EBITDA increased 9.8% sequentially from ₹4.66 crore, and operating margin improved by 50 basis points from 5.8% to 6.3%. However, profit before tax declined 3.5% from ₹2.09 crore, while net profit fell 11.4% from ₹1.30 crore. Net margin narrowed to 1.4% from 1.6%.

The difference between operating and net-profit movement is relevant for investors because it shows that higher EBITDA did not fully translate into higher quarterly profit after tax. Tax expense rose to ₹0.87 crore in Q2 FY27 from ₹0.79 crore in Q1 FY27, while the company also reported negative other income of ₹0.83 crore.

What is driving Balaxi Pharmaceuticals' operations?

Balaxi Pharmaceuticals said its Jadcherla formulation plant received World Health Organization Good Manufacturing Practices certification from the Central Drugs Standard Control Organisation. The certification is an operational development for the company because it supports manufacturing compliance at the facility.

Commercial production at the Jadcherla plant is being progressively scaled up. The initial markets identified by the company are Angola and the Dominican Republic. The results statement did not provide a revenue contribution from the facility or a specific timeline for the scale-up.

The company approved both standalone and consolidated unaudited results for the quarter and half year ended 30 September 2026. The headline financial figures in this report are consolidated figures. On a standalone basis, Balaxi Pharmaceuticals reported revenue of ₹26.29 crore and net profit of ₹0.11 crore for Q2 FY27, illustrating the difference between the company-only and consolidated financial statements.

Why do the Q2 FY27 results matter to investors?

The Q2 result shows a substantial year-on-year improvement in Balaxi Pharmaceuticals' revenue and operating profitability. Revenue growth of 44.8% was accompanied by a 421-basis-point expansion in EBITDA margin, taking the operating margin to 6.29%. Net profit growth was also supported by a low base of ₹0.21 crore in Q2 FY26.

At the same time, the quarter shows that profit growth was not sequentially uniform. Revenue and EBITDA improved from Q1 FY27, but profit after tax and net margin declined. Investors assessing the earnings performance may therefore distinguish between the strong year-on-year comparison and the quarter-on-quarter moderation in net profitability.

The Jadcherla plant's certification and production ramp-up are also relevant operational factors. The company has identified Angola and the Dominican Republic as initial markets, but has not disclosed the plant's capacity, expected sales contribution, or a formal financial target linked to these markets.

Conclusion

Balaxi Pharmaceuticals delivered consolidated Q2 FY27 revenue of ₹81.37 crore and net profit of ₹1.15 crore, with both measures materially above the year-ago quarter. EBITDA growth and margin expansion indicate better operating performance, while the lower sequential net profit highlights that gains at the operating level did not fully carry through to profit after tax.

The next reported indicators to watch are the pace of commercial production at the WHO-GMP-certified Jadcherla plant and its initial supply to Angola and the Dominican Republic. The company has said production is being progressively scaled up, but it has not disclosed a revenue target or a detailed timetable for the expansion.